EcoDrugPlus

Bcl2 Like 2

Ensembl ID : ENSMMNG00015011716
Gene Symbol: BCL2L2
3 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSMMNG00015020882
Gene Symbol: BCL2A1
3 Cross references
114 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSMMNG00015004881
Gene Symbol: BCR
1 Cross references
274 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSMMNG00015010902
Gene Symbol: BTK
3 Cross references
207 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSMMNG00015021385
Gene Symbol: CCR1
3 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSMMNG00015015464
Gene Symbol: CCR4
1 Cross references
254 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSMMNG00015021408
Gene Symbol: CCR5
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSMMNG00015021306
Gene Symbol: CCR9
1 Cross references
262 Possible Orthologues:

C-X-C Chemokine Receptor Type 2-Like

Ensembl ID : ENSMMNG00015006453
Gene Symbol: LOC114897267
2 Cross references
233 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSMMNG00015019109
Gene Symbol: CXCL8
3 Cross references
183 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSMMNG00015005885
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSMMNG00015008191
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).